Michieli M, Raspadori D, Damiani D, Geromin A, Gallizia C, Michelutti A, Fanin R, Fasola G, Russo D, Tazzari P
Institute of Experimental and Clinical Morphology, University of Udine School of Medicine, Italy.
Br J Haematol. 1991 Apr;77(4):460-5. doi: 10.1111/j.1365-2141.1991.tb08610.x.
The expression of the multidrug resistance (MDR)-associated 170 kDa glycoprotein (p170) was investigated in 63 cases of B-cell chronic lymphocytic leukaemia (CLL), with two monoclonal antibodies (MRK-16 and C-219). By immunocytochemistry with MRK-16 (63 cases), the great majority of the cells was positive, with a weak reaction in 61% of cases and a strong reaction in 39% of cases. By flow cytometry, the proportion of positive cells was 39 +/- 25% with MRK-16 (63 cases), and 23 +/- 22% with C-219 (36 cases). The expression of p170 in leukaemic B-lymphocytes suggests that also in B-CLL the development of MDR can have some therapeutic relevance. By either method the proportion of positive cells was not related to prior treatment, time from diagnosis, absolute lymphocyte count, and clinical stage (Rai's and workshop classifications), but 12 patients who were under treatment with alpha-interferon had more positive cells than the other ones.
运用两种单克隆抗体（MRK - 16和C - 219），对63例B细胞慢性淋巴细胞白血病（CLL）患者多药耐药（MDR）相关的170kDa糖蛋白（p170）的表达情况进行了研究。通过MRK - 16免疫细胞化学法（63例）检测，绝大多数细胞呈阳性，其中61%的病例反应较弱，39%的病例反应较强。通过流式细胞术检测，MRK - 16（63例）检测的阳性细胞比例为39±25%，C - 219（36例）检测的阳性细胞比例为23±22%。白血病B淋巴细胞中p170的表达提示，在B - CLL中多药耐药的发生也可能具有一定的治疗意义。无论采用哪种方法，阳性细胞比例均与既往治疗、诊断时间、绝对淋巴细胞计数及临床分期（Rai分期和研讨会分类）无关，但12例接受α干扰素治疗的患者阳性细胞比其他患者更多。
